Therapeutics targeting CTLA-4 or PD-1/PD-L1 have achieved obvious outcomes in advanced HCC, but they are limited when used in combination because of immune-related adverse events, such as hepatitis (40). This evidence concerns the gene CD274 and Hepatitis.